Jul 2019 — Present
Chief executive officer and representative director
Aoritsune Therapeutics
- Sector
- Established prescription medicines and hospital products
- Ownership
- Listed mid-cap with a founding-family minority holding
- Company scale
- ¥96bn revenue, year ended March 2026
- Employees
- 1,320
- Geography
- Japan; three domestic manufacturing sites
- Reporting to
- Board of directors
- Team
- 8 executive reports; 1,320 employees
- Financial scope
- Enterprise P&L; ¥96bn annual revenue
Mandate
Strengthen supply dependability while preserving the authority and capacity of the quality organisation.
Outcomes
- Reduced investigations older than ninety days from 47 to 13 over eighteen months.
- Completed six alternative-source qualifications for eight selected materials.
- Approved a ¥1.1bn enabling phase before reconsidering a larger site expansion.
- Reported ¥180m additional annual cost for the maintained supply alternatives.
Decisions in context
I took the CEO role with a clear need to connect the company's growth plans to the work required to support them. The investigation backlog became an early test of that responsibility. I funded specialist capacity and accepted that some cases would remain open after the headline count improved. Our supply programme required a similar distinction between progress and completion: six alternatives became usable, while two remained unresolved. I also changed the sequence of a major capital request after testing assumptions about laboratory and review capacity. These decisions required me to explain additional expense and revised timing to directors and shareholders. My role is to make the commercial consequences explicit while preserving the relevant technical authority. I continue to examine whether the portfolio and investment plan give the organisation enough capacity to support the obligations already accepted.
Reason for the move
Current appointment; continuing the manufacturing and portfolio programme.
Apr 2014 — Jun 2019
Chief operating officer
Aoritsune Therapeutics
- Sector
- Domestic pharmaceutical manufacturing
- Ownership
- Listed company with continuing founder-family investment
- Company scale
- ¥62bn–¥82bn annual revenue during tenure
- Employees
- 1,040–1,210
- Geography
- Three sites in Japan
- Reporting to
- Chief executive officer
- Team
- 6 direct reports; 890 manufacturing, engineering and supply colleagues
- Financial scope
- ¥31bn annual operating expenditure at midpoint of tenure
Mandate
Bring site plans, capital requirements and commercial commitments into one operating review.
Outcomes
- Managed the enterprise response to a nineteen-day batch hold without intervening in disposition authority.
- Recorded ¥590m shifted invoicing and ¥46m additional investigation and scheduling cost.
- Reduced unplanned schedule changes in a defined site cohort from 29 to 16 per quarter.
Decisions in context
Aoritsune gave me responsibility for an operating network larger and more varied than the one I had previously coordinated. I began by comparing how the sites described available capacity and where their assumptions differed from the commercial plan. The work involved finance and quality colleagues as well as production. A held-batch episode became a defining test: I organised specialist support, revised the forecast and established customer communication while the authorised quality process continued. The immediate cost was visible, and I did not ask the site to make it disappear through a more convenient technical conclusion. I also prepared several capital recommendations whose benefits depended on work outside the proposed equipment investment. These experiences made the eventual CEO succession a broader enterprise mandate, rather than simply an extension of my authority over manufacturing operations.
Reason for the move
Selected by the board to succeed the retiring chief executive.
Oct 2009 — Mar 2014
Chief supply officer
Nerukawa Biologics
- Sector
- Hospital medicines and pharmaceutical production
- Ownership
- Privately held industrial group subsidiary
- Company scale
- ¥28bn–¥39bn annual company revenue
- Employees
- 640
- Geography
- Two Japanese sites and domestic distribution partners
- Reporting to
- Managing director
- Team
- 5 direct reports; 120 planning, procurement and distribution staff
- Financial scope
- ¥12.8bn annual procurement and supply expenditure
Mandate
Reduce avoidable supply complexity while maintaining explicit customer-transition obligations.
Outcomes
- Reviewed twenty-three low-volume variants across a defined product group.
- Completed managed discontinuation of seven variants and revised planning for five others.
- Reduced annual changeovers in the reviewed group by 17% after a twenty-month transition.
Decisions in context
Supply leadership showed me how commercial choices become manufacturing work long before a production schedule is issued. I coordinated procurement, planning and distribution, but many of the important decisions required agreement with colleagues outside those functions. The portfolio review was particularly instructive. Operations could describe the cost of variation; commercial teams could describe customer relationships; quality and technical specialists could explain the conditions around change. I brought those accounts into a common decision process and resisted a blanket reduction based only on volume. Seven variants ultimately left the range through a managed transition, while others remained for reasons we could articulate. I learnt to include inventory, communication and specialist workload in the economics of simplification. The move to Aoritsune offered a chance to carry those choices across an entire operating network and a more demanding capital programme.
Reason for the move
Recruited into a wider listed-company operating mandate at Aoritsune.
Jan 2004 — Sept 2009
Site head
Nerukawa Biologics
- Sector
- Established sterile hospital-product manufacture
- Ownership
- Private industrial group subsidiary
- Company scale
- ¥11bn–¥17bn annual company revenue
- Employees
- 310 at the site
- Geography
- Japan
- Reporting to
- Managing director
- Team
- 7 site leads; 310 site employees
- Financial scope
- Approximately ¥8.4bn annual site expenditure
Mandate
Improve site dependability without moving production constraints into testing and release work.
Outcomes
- Raised availability on the reviewed equipment group from 71% to 79%.
- Revised the output plan after identifying a downstream testing constraint.
- Established joint workload reviews covering twelve recurring site dependencies.
Decisions in context
My first site-head appointment required me to bring engineering, production and people decisions together. I had enough technical experience to question an explanation, but I needed to learn when to stop offering an engineering solution and ask the accountable specialist to define the decision. The early availability programme made that lesson tangible. Better equipment performance increased output, yet testing and review work did not expand automatically with it. We revised the plan and funded the relevant capability rather than treating the additional queue as a failure elsewhere. I also developed site managers who could present unresolved dependencies clearly without waiting for me to translate them. The appointment established my interest in the complete operating path. Promotion into supply leadership then exposed the product and commercial choices that determined much of the workload arriving at the site.
Reason for the move
Promoted to coordinate supply across the company's two sites.
Apr 1998 — Dec 2003
Quality operations manager
Kisarame Laboratories
- Sector
- Established prescription-product manufacture
- Ownership
- Privately owned Japanese manufacturer
- Company scale
- ¥7bn–¥11bn annual revenue
- Employees
- 230
- Geography
- Japan
- Reporting to
- Quality director
- Team
- 22 quality-operations colleagues
- Financial scope
- ¥460m annual departmental budget
Mandate
Improve investigation coordination and the completeness of manufacturing records.
Outcomes
- Introduced remaining-evidence reviews for thirty-four active investigations.
- Reduced repeat documentation queries in a reviewed group from 18 to 7 per month.
- Trained six colleagues to coordinate cross-functional investigation work.
Decisions in context
Moving from engineering into quality operations changed the questions I asked about a manufacturing problem. I became less interested in whether an explanation sounded technically plausible and more interested in whether the available record supported it. My team coordinated evidence, documentation and follow-up under the quality director's authority. I learnt to distinguish administrative delay from a genuine need for further work, and to identify where specialist capacity outside the department was limiting progress. We improved coordination without giving the team a simple quota for closing files. I also learnt how easily an executive request for a date could be heard as a preference for a particular answer. The later site appointment gave me responsibility for the operating conditions around those decisions, while preserving respect for the quality organisation's distinct authority and the limits of my own remit.
Reason for the move
Accepted a site-leadership role to broaden operating accountability.
Apr 1992 — Mar 1998
Process engineer
Kisarame Laboratories
- Sector
- Medicine process engineering and manufacture
- Ownership
- Independent private company
- Company scale
- ¥4bn–¥7bn annual revenue
- Employees
- 170
- Geography
- Japan
- Reporting to
- Manufacturing engineering manager
- Team
- Individual contributor in an eight-person engineering group
- Financial scope
- Technical work on projects of ¥20m–¥90m; no independent capital or release authority
Mandate
Document process behaviour and support controlled equipment and operating changes.
Outcomes
- Prepared technical records for eleven equipment-change projects.
- Mapped fourteen recurring process observations for specialist review.
- Reduced repeated data-collection work on one process study by 26%.
Decisions in context
I entered manufacturing directly from my engineering degree and spent the first years learning how much detail sits behind a routine production description. I collected process data, prepared equipment-change records and worked with experienced colleagues on unexpected observations. My authority was limited: I could propose an explanation and assemble evidence, but I could not approve a release or commit the company to a capital project. That boundary helped me learn to write technical material another responsible person could evaluate. I also discovered that a missing record can consume more time than an apparently difficult calculation. The move into quality operations followed several assignments where coordination and evidence were as important as engineering analysis. It began a career interest in how organisations preserve the meaning of an observation as it moves towards a consequential decision.
Reason for the move
Transferred into quality operations after cross-functional investigation assignments.
What I am looking for next
I intend to complete the current operating programme at Aoritsune before considering another executive mandate. The work still includes unresolved supply alternatives, a staged capacity decision and a more explicit account of portfolio complexity. For a subsequent CEO role, I would consider an established medicines or specialist manufacturing business whose board wants to connect growth with the capability required to sustain it. I would not be the right candidate for a remit defined principally by rapid cost removal before the operating obligations were understood. At present, one external board contribution may be possible within eighteen days a year, subject to employer approval and a detailed conflict review. I would prefer a company outside our direct product and supplier relationships, with a chair seeking manufacturing judgement and an executive team willing to expose uncertainty clearly. The role should have a defined committee contribution and enough access for a proper induction. A title without the conditions needed to contribute would not be a useful next step for either party.